Financial Performance - The company achieved a revenue of 318 million CNY in the first three quarters of 2024, representing a year-on-year growth of 30.2% [1] - The net profit attributable to shareholders was -6.74 million CNY, while the net cash flow from operating activities was 49.72 million CNY, showing a year-on-year increase of 37.18% [1] Product Development and Market Performance - The Nova stent's sales volume in the first three quarters approached the total sales of the previous year, indicating a steady growth despite not winning bids in the "3+N" procurement in Hebei [2] - The company maintains a stable pricing strategy for the Nova stent, considering both domestic and international market prices for future products like the self-expanding drug-eluting stent [2] - The revenue distribution for coronary and neuro-interventional products in the first three quarters was approximately 55% and 45%, respectively [4] Research and Development - The company has consistently maintained a high proportion of R&D investment, focusing on innovative products in the neuro-interventional field [3] - R&D expenses increased by approximately 5-6 million CNY in the third quarter, driven by clinical trials and product registrations [6] - Future R&D investments will focus on high-value products, with a potential decrease in R&D expenditure as revenue grows [6] Regulatory and Market Strategy - The company is in the process of registering the mesh stent, with expectations to obtain approval next year [3] - The company is actively preparing for the commercialization of the self-expanding stent, with a robust sales team in place [6] - The FDA submission for coronary stents is progressing smoothly, with expectations to submit final materials soon, which will enhance production processes and cost efficiency [5]

证券代码：688108 证券简称：赛诺医疗 公告编号：2024-056 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 2024 年 10 月 28 日（美国时间 10 月 27 日），耶鲁大学医学院的 Alexandra J. Lansky 教授代表研究团队在第 36 届经导管心血管治疗学术会议（TCT2024）上公 布了赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）首创研 发生产的，以促进愈合为导向的新型药物洗脱支架系统 HT Supreme™在美国、日本、 欧洲进行的 PIONEER-III 临床试验研究五年期随访结果。 该研究结果表明：HT Supreme™支架试验组相比于对照组（Xience 系列和 Promus 系 列支架），第 2 至 5 年总体靶病变失败率（TLF）6.7% vs 8.0%（P=0.39），靶血管 失败率（TVF）8.5% vs 10.2%（P=0.28），主要心脏不良事件率（MACE）14.0% vs 15.6%（P=0.36），支架内血栓发生率（ST）1. ...

证券代码：688108 证券简称：赛诺医疗 公告编号：2024-058 赛诺医疗科学技术股份有限公司 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）第三届 监事会第四会议通知于 2024 年 10 月 23 日以书面送达等方式通知各位监事。会议于 2024 年 10 月 29 日在北京市海淀区高梁桥斜街 59 号中坤大厦 7 层公司会议室以现场 和通讯相结合的方式召开。本次会议应出席监事 3 人，实际出席监事 3 人。本次会 议由监事会主席于长春先生召集并主持，公司部分高管列席本次会议。本次会议的 召开符合《中华人民共和国公司法》等有关法律法规、规范性文件及《赛诺医疗科 学技术股份有限公司章程》《赛诺医疗科学技术股份有限公司监事会议事规则》等 的规定，会议的召开程序合法有效。 经与会监事认真讨论，审议并通过如下事项： 1、审议通过"关于赛诺医疗科学技术股份有限公司 2024 年第三季度报告的议 案" 表决结果：同意 3 票；反对 0 票；弃权 0 票 2、审议通过"赛诺医疗科学技术股份有限公司关于向中国农业银行股份有限公 司天津经济技术开发区分行申请授信额度的议案" 关于第三届监事会第四次会议 ...

赛诺医疗科学技术股份有限公司 重大信息内部报告制度 第一章 总则 第一条 为保证赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"） 信息披露及时、准确、真实、完整，明确公司重大信息的收集和管理办法，完善信息报告联 络渠道，确保公司规范运作，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 海证券交易所科创板股票上市规则》（以下简称" 《科创板上市规则》"）《上市公司信息披露 管理办法》《赛诺医疗科学技术股份有限公司章程》（以下简称" 《公司章程》"）《赛诺医疗科 学技术股份有限公司信息披露管理制度》等有关规定，结合公司实际，特制定本制度。 第二条 重大信息内部报告是指当出现、发生或即将发生可能对公司股票及其衍生品种 交易价格或对投资者决策产生较大影响的情形或事项时，按照本制度规定负有报告义务的有 关人员、部门和单位，应当及时将有关信息通过公司证券事务部、董事会秘书、董事长向董 事会报告。 第三条 本制度适用于公司及合并报表范围内的全资及控股子公司、分公司及其他各相 关分支机构、以及公司能够实施重大影响的参股公司。 第二章 重大信息报告义务人及职责 第四条 本制度所称"重大信息报告义务人"主 ...

证券代码：688108 证券简称：赛诺医疗 公告编号：2024-060 赛诺医疗科学技术股份有限公司 关于制订部分公司治理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）于 2024 年 10 月 29 日召开第三届董事会第四次会议，审议通过"赛诺医疗科学技术股份有限公司关于制订《重大 信息内部报告制度》《舆情管理办法》等公司治理制度的议案"。根据《中华人民共和国公司 法》《中华人民共和国证券法》等法律、法规、规范性文件以及《赛诺医疗科学技术股份有限 公司章程》等的规定，为进一步完善公司治理结构、促进规范运作，并结合公司实际情况，公 司制定了《赛诺医疗科学技术股份有限公司重大信息内部报告制度》《赛诺医疗科学技术股份 有限公司舆情管理办法》，上述公司制度均由董事会负责制定和解释，自董事会审议通过之日 起生效，无需提交公司股东大会批准。 具体内容详见公司于同日在中国证监会指定信息披露媒体上海证券交易所网站 （www.sse.com.cn）上披露的《赛诺医 ...

证券代码：688108 证券简称：赛诺医疗 公告编号：2024-059 赛诺医疗科学技术股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、本次申请授信额度的基本情况 二、对公司的影响 公司本次向金融机构申请的综合授信额度总金额：1.2 亿元 使用期限：本次综合授信额度自董事会决议生效之日起有效期 2 年，有效期内可 多次审批，授信额度可循环使用。 关于向金融机构申请授信额度的公告 为满足赛诺医疗科学技术股份有限公司（以下简称"公司"或"赛诺医疗"）业 务发展及经营需要，进一步拓宽融资渠道，优化公司资本结构，公司于2024年10月29 日召开第三届董事会第四次会议、第三届监事会第四次会议，分别审议通过《赛诺医 疗科学技术股份有限公司关于向中国农业银行股份有限公司天津经济技术开发区分 行申请授信额度的议案》。公司拟向中国农业银行股份有限公司天津经济技术开发区 分行申请总计不超过人民币1.2亿元的综合授信额度，用于办理包括但不限于人民币 /外币贷款，开具银行承兑汇票、信用证、保函，汇票贴现等在内 ...

舆情管理办法 赛诺医疗科学技术股份有限公司 第一章 总则 第一条 为提高赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）应 对各类网络舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类网络舆情对公 司品牌形象、商业信誉、股价及正常生产经营活动造成的影响，切实保护投资者合法权益， 根据《上海证券交易所科创板股票上市规则》等相关法律法规、规范性文件及《赛诺医疗科 学技术股份有限公司章程》的相关规定，并结合公司实际情况，制定本办法。 第二条 本办法所称网络舆情包括但不限于下列内容： （一）报刊、电视、网络等媒体对公司进行的负面报道、不实报道； （二）社会上存在的已经或将会给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较大影响的事 件信息。 第三条 舆情信息的分类： （一）重大舆情：指传播范围较广，严重影响公司公众形象或正常经营活动，使公司已 经或可能遭受损失，已经或可能造成公司股票及衍生品种交易价格异常变动的负面舆情。 （二）一般舆情：指除重大舆情之外的其他舆情。 第四条 ...

证券代码：688108 证券简称：赛诺医疗 公告编号：2024-057 赛诺医疗科学技术股份有限公司 关于第三届董事会第四次会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）第三届董 事会第四次会议通知于 2024 年 10 月 23 日以书面方式送达各位董事和监事。会议于 2024 年 10 月 29 日以现场和通讯相结合的方式在公司会议室召开。本次会议应出席董 事 9 人，实际出席董事 9 人。本次会议由董事长孙箭华先生召集并主持，公司监事、 高管列席了本次会议。本次会议的召开符合《中华人民共和国公司法》等有关法律、 法规、规范性文件及赛诺医疗《赛诺医疗科学技术股份有限公司章程》《赛诺医疗科 学技术股份有限公司董事会议事规则》等的规定，会议召开程序合法有效。 二、董事会会议审议情况 经与会董事认真讨论，审议并通过如下事项： 1、审议通过"关于赛诺医疗科学技术股份有限公司 2024 年第三季度报告的议案" 经与会董事审议， ...

Revenue and Sales Performance - Revenue for the third quarter was RMB 104.79 million, a 25.76% increase year-over-year[3] - Year-to-date revenue reached RMB 318.49 million, up 30.20% compared to the same period last year[3] - The increase in revenue was primarily driven by a significant growth in sales of coronary products[7] - Total operating revenue for the first three quarters of 2024 reached 318,486,443.24 RMB, a significant increase from 244,617,074.10 RMB in the same period of 2023[16] - Sales revenue from goods and services reached 358,433,488.89 RMB, a notable increase from the previous year[20] Net Profit and Loss - Net loss attributable to shareholders for the third quarter was RMB -14.41 million[3] - Year-to-date net loss attributable to shareholders was RMB -6.74 million[3] - Net profit attributable to the parent company's shareholders was -241,473,911.19 RMB in Q3 2024, slightly worse than -234,729,458.31 RMB in 2023[15] - Net profit attributable to parent company shareholders was -6,744,452.88 RMB, a significant loss compared to the previous year[18] - Total comprehensive income was -6,900,442.91 RMB, indicating a substantial decline in overall financial performance[18] - Basic earnings per share were -0.02 RMB, indicating a loss per share[18] R&D Investment and Expenses - R&D investment for the third quarter was RMB 59.72 million, a 58.46% increase year-over-year[3] - Year-to-date R&D investment totaled RMB 151.95 million, up 28.67% compared to the same period last year[3] - R&D expenses increased to 106,407,498.18 RMB in the first three quarters of 2024, up from 80,498,702.34 RMB in 2023[16] Assets and Liabilities - Total assets as of the end of the reporting period were RMB 1.28 billion, a 7.95% increase from the end of the previous year[4] - Equity attributable to shareholders was RMB 857.51 million, a 4.58% increase from the end of the previous year[4] - Total assets as of Q3 2024 stood at 1,280,072,535.51 RMB, up from 1,185,821,379.98 RMB in the previous year[13][15] - Total liabilities for Q3 2024 were 381,222,588.88 RMB, compared to 324,171,588.85 RMB in 2023[14][15] - Long-term liabilities increased to 224,481,917.36 RMB in Q3 2024, compared to 172,899,093.28 RMB in 2023[14] - Development expenditure rose to 377,364,683.16 RMB in Q3 2024, up from 331,823,588.24 RMB in 2023[13] - Inventory levels slightly increased to 120,649,871.70 RMB in Q3 2024 from 118,220,173.59 RMB in the previous year[13] Cash Flow and Liquidity - Operating cash flow for the year-to-date period was RMB 49.72 million, a 37.18% increase year-over-year[3] - Cash flow from operating activities increased to 49,720,487.28 RMB, showing improved operational efficiency[20] - Cash flow from investing activities was -72,000,968.51 RMB, reflecting significant investment outflows[21] - Cash flow from financing activities was 59,422,575.01 RMB, indicating strong external funding support[21] - Total cash and cash equivalents at the end of the period were 224,939,661.92 RMB, showing a healthy liquidity position[21] - Total cash inflow from financing activities was 121,906,687.94 RMB, highlighting robust fundraising efforts[21] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period is 10,402[9] - Tianjin Weixin Sunshine Enterprise Management Consulting Co., Ltd. holds 71,859,417 shares, representing 17.38% of total shares[9] - Guo Yanchao holds 22,770,854 shares, representing 5.51% of total shares[9] - China Bank - Guotai Jiangyuan Advantage Selection Flexible Allocation Mixed Securities Investment Fund holds 12,295,278 shares, representing 2.97% of total shares[9] - Tianjin Sunshine Guangye Enterprise Management Partnership holds 10,628,155 shares, representing 2.57% of total shares[9] - Huang Songlang holds 10,000,000 shares, representing 2.42% of total shares[9] - Tianjin Sunshine Deye Enterprise Management Partnership holds 8,208,381 shares, representing 1.99% of total shares[9] - Li Guangxin holds 7,852,056 shares, representing 1.90% of total shares[9] - China Bank - Guotai Zhiyuan Advantage Mixed Securities Investment Fund holds 7,642,073 shares, representing 1.85% of total shares[9] - China Construction Bank - Guotai Pharmaceutical Health Equity Securities Investment Fund holds 7,246,706 shares, representing 1.75% of total shares[10] Operating Costs and Expenses - Operating costs for the first three quarters of 2024 amounted to 355,578,619.17 RMB, compared to 301,656,954.40 RMB in 2023[16] - Total assets impairment loss was -7,904,949.40 RMB, reflecting significant write-downs[18]

Company Updates - The company's subsidiary, Sinomed Shenchang, showcased its innovative products, including the self-expanding intracranial drug-coated stent and the flow-diverter coated mesh stent, at the OCIN 2024 conference [1] - The company's self-developed COMETIU stent, the world's first self-expanding intracranial drug-coated stent, passed the NMPA's innovative medical device approval in April 2024 and was submitted for domestic medical device registration in May 2024 [1] - The COMETIU stent demonstrated a post-operative 6-month in-stent restenosis (ISR) rate of 1.72% and a stroke or death rate of 3.13% in clinical trials [1] - The company's flow-diverter coated mesh stent, another innovative product, showed promising results in a single-center clinical trial at Wuhan Union Hospital, with 27 patients and 29 aneurysms included in the study [1] - The flow-diverter coated mesh stent achieved a Raymond I rate of 88.46% and a Raymond I+II rate of 87.88% at 6 months, and a Raymond I+II rate of 92.41% at 1 year, with no post-operative stroke events reported [2] - The company's flow-diverter coated mesh stent is the first in China to be delivered via a 017 system, featuring a new alloy material, proprietary electronic coating grafting technology, and the smallest delivery profile globally [2] - The company's neurovascular business is entering a harvest period with the upcoming market entry of its innovative products, including the flow-diverter coated mesh stent [3] Industry Insights - Intracranial atherosclerotic stenosis (ICAS) is a common cause of ischemic stroke, particularly in Asian populations, with higher recurrence rates as stenosis severity increases [1] - Intracranial stent placement has become a highly anticipated treatment for ICAS, with the COMETIU stent significantly reducing post-operative restenosis rates and stroke or death rates [1] - The company's product pipeline, including the NOVA intracranial drug-eluting stent approved in 2021 and the intracranial thrombectomy stent approved in the first half of 2023, positions it to meet diverse stent needs for ischemic stroke intervention [2]